Scientist Home Future Health Limited filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on October 30, 2026, reporting a nine-month net loss of $191,712 and a shift to stockholders' deficit.

Key Highlights

  • Nine-month net loss: The company reported a net loss of $191,712 for the nine months ended September 30, 2026, compared to a net loss of $78,999 for the same period in 2025, according to the filing.
  • Q3 net income: For the three months ended September 30, 2026, the company recorded net income of $8,212, compared to a net loss of $47,845 in the prior-year quarter.
  • Revenue growth: Total revenues for the nine months ended September 30, 2026 were $485,043, versus $115,980 for the nine months ended September 30, 2025.
  • Stockholders' deficit: Total stockholders' deficit stood at $(78,205) as of September 30, 2026, compared to stockholders' equity of $113,391 as of December 31, 2025.
  • Cash position: Cash and cash equivalents were $13,653 as of September 30, 2026, down from $68,888 as of December 31, 2025.
  • Shares outstanding: 23,716,000 shares of common stock were issued and outstanding as of October 30, 2026.
  • Related-party reliance: Cost of revenues to a related party for the nine months ended September 30, 2026 totaled $275,846, and the amount due to a related party on the balance sheet was $264,437.

Scientist Home Future Health Q3 2026 Financial Results and Balance Sheet Position

According to the filing, Scientist Home Future Health Limited, a Nevada-incorporated company headquartered in Kwun Tong, Kowloon, Hong Kong, generated total revenues of $485,043 for the nine months ended September 30, 2026, consisting of retail trading revenue of $474,779 and service revenue of $10,264. This compares to total revenues of $115,980 for the nine months ended September 30, 2025, which consisted solely of retail trading revenue. The company's gross profit for the nine-month period was $209,197, up from $49,298 in the comparable prior-year period.

Despite improved gross profit, the filing disclosed that selling, general and administrative expenses for the nine months ended September 30, 2026 were $400,909, compared to $128,297 in the prior-year period, resulting in an operating loss of $191,712 for the nine-month period. However, the company reported an operating income of $8,212 for the three months ended September 30, 2026 alone, reflecting improvement in the most recent quarter. The accumulated deficit as of September 30, 2026 was $438,417, versus $246,705 as of December 31, 2025.

The balance sheet as of September 30, 2026 showed total assets of $607,898 and total liabilities of $686,103, the latter driven in part by an amount due to a related party of $264,437 and lease liabilities of $332,713 in aggregate. The filing noted that the securities registered pursuant to Section 12(b) of the Act showed "N/A" for title of class, trading symbol, and exchange, indicating no securities are listed on a national exchange under Section 12(b). The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

What Was Disclosed

Scientist Home Future Health Limited disclosed unaudited financial results for the nine months ended September 30, 2026, showing increased revenues but a wider net loss year-over-year, a shift from positive stockholders' equity to a deficit of $(78,205), and significant related-party transactions in both cost of revenues and liabilities.